EVALUATION OF THE EFFECTIVENESS OF METABOLIC THERAPY IN THE TREATMENT OF DIABETIC POLYNEUROPATHIES IN PATIENTS WITH TYPE 2 DIABETES

DOI: https://doi.org/10.29296/25877313-2020-10-04
Issue: 
10
Year: 
2020

I.N. Pashkova assistant of the Department of pharmacology and pharmaceutical consulting with a postgraduate course, Federal state budgetary educational institution of higher education "Krasnoyarsk state medical University named after Professor V.F. Voino-Yasenetsky" of the Ministry of health of the Russian Federation (Krasnoyarsk) T.V. Potupchik Ph.D. (Medical), Associate Professor, Department of pharmacology and pharmaceutical consulting with a postgraduate course, Federal state budgetary educational institution of higher education "Krasnoyarsk state medical University named after Professor V.F. Voino-Yasenetsky" of the Ministry of health of the Russian Federation (Krasnoyarsk) I.V. Gackich Ph.D. (Medical), Associate Professor, Department of pharmacology and pharmaceutical consulting with a postgraduate course, Federal state budgetary educational institution of higher education "Krasnoyarsk state medical University named after Professor V.F. Voino-Yasenetsky" of the Ministry of health of the Russian Federation (Krasnoyarsk) M.M. Petrova Dr.Sc. (Medical), Professor, first Vice-rector, Head of the Department of outpatient therapy and family medicine with a postgraduate course, Federal state budgetary educational institution of higher education "Krasnoyarsk state medical University named after Professor V.F. Voino-Yasenetsky" of the Ministry of health of the Russian Federation (Krasnoyarsk) O.F. Veselova Associate Professor, Head of the Department of pharmacology and pharmaceutical consulting with a postgraduate course, Federal state budgetary educational institution of higher education "Krasnoyarsk state medical University named after Professor V.F. Voino-Yasenetsky" of the Ministry of health of the Russian Federation (Krasnoyarsk) A.N. Narkevich Ph.D. (Medical), Associate Professor, Head of the Department of medical Cybernetics and Informatics, Federal state budgetary educational institution of higher education "Krasnoyarsk state medical University named after Professor V.F. Voino-Yasenetsky" of the Ministry of health of the Russian Federation (Krasnoyarsk) T.P. Shalda Senior Lecturer, Department of pharmacology and pharmaceutical consulting with a postgraduate course, Federal state budgetary educational institution of higher education "Krasnoyarsk state medical University named after Professor V.F. Voino-Yasenetsky" of the Ministry of health of the Russian Federation (Krasnoyarsk)

The aim of this study was to study the effectiveness of metabolic therapy in the treatment of polyneuropathy in patients with type 2 diabetes mellitus. The results of treatment of 110 patients with type 2 diabetes were analyzed. To study the efficacy and safety of metabolic drugs, patients were divided into 4 parallel groups: Group 1 (Control group), patients receiving only basic hypoglycemic therapy; group 2 (Cocarnit), patients who, in addition to basic hypoglycemic therapy, received a combined metabolic drug – "Cocarnit"; Group 3 (Cytoflavin), patients who, in addition to basic hypoglycemic therapy, received the combined metabolic drug "Cytoflavin"; group 4 (Thioctacid), patients who, in addition to basic hypoglycemic therapy, received the drug thioctic acid "Thioctacid". All patients were tested for TSS, NSS,NDS, SF-36, neurophysiological study – ENMG, as well as determination of VEGF in blood serum in dynamics in order to evaluate the effectiveness of metabolic therapy 24–48 hours before and after 36-40 days of therapy. According to the TSS and NSS scales, patients who received Cocarnit, Cytoflavin, and Thioctic acid had significantly higher confidence differences before and after thera-py (p

Keywords: 
type 2 diabetes mellitus
diabetic polyneuropathy
thioctic acid
cocarnitol
cytoflavin
metabolic therapy
electroneuromyography

References: 
  1. Algorithms of specialized medical care for patients with diabetes mellitus. Edited by I.I. Dedov, M.V. Shestakova, A.Yu. Mayorov. M. 2019.
  2. Vertkin A.L., Knorring, G.Yu., Magomedova A.U. diabetes mellitus and diabetic neuropathy: continuing the conversation. An Outpatient ap-pointment. 2016; 3(6):8–13.
  3. Vorobyova O.V. Thioctic (alpha-lipoic) acid-spectrum of clinical application. Journal of neurology and psychiatry named after S.S. Korsakov. 2011; 10:86–90.
  4. Gatskikh I.V., Brikman I.N., Gazenkampf K.A., Petrova M.M., Veselova O.F., Shal'da T.P., Narkevich A.N., Potupchik T.V. Dynamics of neuro-logical disorders against the background of combined therapy in patients with type 2 diabetes. Journal of neurology and psychiatry named after C.C. Korsakov. 2018; 6:31–6. DOI:10.17116/jnevro20181186131
  5. Gatskikh I.V., Petrova M.M., Veselova O.F., Shal'da T.P., Narkevich A.N., Brikman I.N. Analysis of cognitive status in patients with type 2 dia-betes. Diabetes Mellitus. 2017; 20(6):434–440. DOI:10.14341/DM7926
  6. Devlikamova F.I. Application of the drug kokarnit in the treatment of patients with diabetic polyneuropathy. Journal of neurology and psychi-atry named after S.S. Korsakov, 2016; 11:64–68. DOI:10.17116/jnevro201611611164-68
  7. Karakulova Yu.V., Filimonova T.A. Monitoring of clinical and neurophysiological parameters in diabetic polyneuropathy in the process of met-abolic therapy. Doctor.ru. 2017; 1:25–29.
  8. Clinical guidelines for neurology of the European Federation of neurological communities. Ed. Gilhus N.E., Barnes M.P., Brain M. Scientific. editor of the Russian edition Nikitin S.S. M.; 2012.
  9. Konenkov V.I., Borodin Yu.I., Lyubarsky M.S. Lymphology. Russian Academy of medical Sciences, Siberian branch, Research Institute of clini-cal and experimental lymphology. Novosibirsk: Manuscript, 2012.
  10. Michurova M.S., Kalashnikov V.Yu., Smirnova O.M., Kononenko I.V., Ivanova O.N. the Role of endothelial progenitor cells in the develop-ment of complications of diabetes mellitus. Diabetes. 2015; 1:24–32. DOI: 10.14341/DM2015124-32
  11. Mkrtumyan A. M., Markova T. N., Podacima S. V. the use of the drug Kokarna in the treatment of diabetic polyneuropathy. Endocrinology. 2016; 4:6–10.
  12. Muz V.A., Zubkova S.T., Samson A.Ya. Possibilities of Cytoflavin in the treatment of lipoid necrobiosis in adolescents with diabetes mellitus. Diabetes and heart. 2012; 2:82–85.
  13. Pashkova I.N., Potupchik T.V., Petrova M.M., Veselova O. F., Gatskikh I. V. Complex therapy of polyneuropathy in patients with type 2 dia-betes mellitus. Doctor. 2018; 9: 37–43. DOI: https://doi.org/10.29296/25877305-2018-09-08
  14. Rachin A.P., Sharov M.N. Comparative open randomized study on evaluating the effectiveness and safety of the drug cocarnit in back pain in patients suffering from diabetic polyneuropathy. Russian medical journal. 2017; 9:586–590.
  15. Khovasova N.O., Naumov A.V., Magomedova A.Yu. Vertkin A.L., Nosova A.V. Diabetic neuropathy: what a polyclinic therapist should know. Outpatient reception. 2016; 2:60–63.
  16. Lerman O.Z., Galiano R.D., Armour M., Levine J.P., Gurtner G.C. Cellular dysfunction in the diabetic fibroblast: impairment in migration, vas-cular endothelial growth factor production, and response to hypoxia. Am. J. Pathol. 2003; 162(1): 303–312.
  17. Maric-Bilkan C., Flynn E.R., Chade A.R. Microvascular disease precedes the decline in renal function in the streptozotocin-induced diabetic rat. Am. J. Physiol. Renal Physiol. 2012; 3:308–315. http://dx.doi.org/10.1152/ajprenal.00421.2011
  18. Shenouda Sh. M., Widlansky M.E., Chen K. et al. Altered Mitochondrial Dynamics Contributes to Endothelial Dysfunction in Diabetes Melli-tus. Circulation, 2011; 4:444–453. http://dx.doi.org/10.1161/CIRCULATIONAHA.110.014506
  19. Modern principles of management of patients with diabetic polyneuropathy. Neuromuscular diseases. 2012; 2:7–19. https://doi.org/10.17650/2222-8721-2012-0-2-7-19.